For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Product Variant B | MyBlu e- igarette variant B (2.4% nicotine) | 0 | None | 0 | 16 | 1 | 16 | View |
| Product Variant A | MyBlu e-cigarette variant A (2.4% nicotine) | 0 | None | 0 | 18 | 3 | 18 | View |
| Product Variant C | MyBlu e-cigarette variant C (2.4% nicotine) | 0 | None | 0 | 16 | 1 | 16 | View |
| Product Variant D | MyBlu e-cigarette variant D (2.4% nicotine) | 0 | None | 0 | 18 | 1 | 18 | View |
| Product Variant E | MyBlu e- cigarette variant E (1.2% nicotine) | 0 | None | 0 | 20 | 2 | 20 | View |
| Product Variant F | MyBlu e-cigarette variant F (1.2% nicotine) | 0 | None | 0 | 20 | 1 | 20 | View |
| Product Variant G | MyBlu e-cigarette variant G (2.4% nicotine) | 0 | None | 0 | 20 | 0 | 20 | View |
| Product Variant H | MyBlu e-cigarette variant H (2.4% nicotine) | 0 | None | 0 | 20 | 1 | 20 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Headache | NON_SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA® Version 22.0 | View |
| Hypoesthesia | NON_SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA® Version 22.0 | View |
| Migraine | NON_SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA® Version 22.0 | View |
| Dysmenorrhea | NON_SYSTEMATIC_ASSESSMENT | Reproductive system and breast disorders | MedDRA® Version 22.0 | View |
| Oropharyngeal discomfort | NON_SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA® Version 22.0 | View |
| Contact dermitits | NON_SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDRA® Version 22.0 | View |
| Constipation | NON_SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDRA® Version 22.0 | View |
| Diarrhea | NON_SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDRA® Version 22.0 | View |